| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| License revenue | 0 | - | 1,000 | - |
| Research and development | 38,913 | 37,125 | 20,439 | 17,097 |
| General and administrative | 9,110 | 12,730 | 9,782 | 3,785 |
| Total operating expenses | 48,023 | 49,855 | 30,221 | 20,882 |
| Operating loss | -48,023 | -49,855 | -29,221 | -20,882 |
| Other income, net | - | - | 2,087 | 2,406 |
| Net loss before income taxes | - | - | -27,134 | -18,476 |
| Other income, net | 371 | 664 | - | - |
| Net loss | -47,652 | -49,191 | -27,134 | -18,476 |
| Net unrealized gain (loss) on marketable securities | 5 | - | - | - |
| Foreign currency translation adjustment | 6 | 18 | 16 | 10 |
| Net unrealized loss on marketable securities | - | -11 | 241 | -2 |
| Comprehensive loss | -47,641 | -49,184 | -26,877 | -18,468 |
| Net loss per share basic (in usd per share) | -2.03 | -2.34 | -1.3 | -0.89 |
| Net loss per share diluted (in usd per share) | -2.03 | -2.34 | -1.3 | -0.89 |
| Weighted-average common shares used to compute net loss per share - basic (in shares) | 23,487,000 | 21,010,000 | 20,876,000 | 20,852,000 |
| Weighted-average common shares used to compute net loss per share - diluted (in shares) | 23,487,000 | 21,010,000 | 20,876,000 | 20,852,000 |
Adverum Biotechnologies, Inc. (ADVM)
Adverum Biotechnologies, Inc. (ADVM)